Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5‑a]pyrazines as ATR Inhibitors
journal contributionposted on 08.01.2015, 00:00 by Paul A Barsanti, Robert J. Aversa, Xianming Jin, Yue Pan, Yipin Lu, Robert Elling, Rama Jain, Mark Knapp, Jiong Lan, Xiaodong Lin, Patrick Rudewicz, Janet Sim, Lorena Taricani, George Thomas, Linda Xiao, Qin Yue
A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines. Use of PI3Kα mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chemistry designs. Detailed DMPK studies involving cyanide and GSH as trapping agents during microsomal incubations, in addition to deuterium-labeled compounds as mechanistic probes uncovered the molecular basis for the observed CYP3A4 TDI in the series.